Free Trial

Mineralys Therapeutics (MLYS) Insider Trading & Ownership

Mineralys Therapeutics logo
$29.28 -0.37 (-1.25%)
Closing price 05/5/2026 04:00 PM Eastern
Extended Trading
$29.28 +0.00 (+0.02%)
As of 05/5/2026 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Mineralys Therapeutics (NASDAQ:MLYS) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
18.94%
Number Of
Insiders Buying
(Last 12 Months)
3
Amount Of
Insider Buying
(Last 12 Months)
$52.35M
Number Of
Insiders Selling
(Last 12 Months)
6
Amount Of
Insider Selling
(Last 12 Months)
$79.36M
Get MLYS Insider Trade Alerts

Want to know when executives and insiders are buying or selling Mineralys Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MLYS Insider Buying and Selling by Quarter

Mineralys Therapeutics Insider and Congressional Trades History

Transaction DateInsiderBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/17/2026Sell416$31.33$13,033.28  
4/15/2026Sell6,348$27.66$175,585.68  
4/13/2026Sell14,058$26.54$373,099.32  
4/13/2026Sell15,730$26.83$422,035.90  
4/9/2026Sell2,170$27.38$59,414.60  
3/31/2026Sell3,000$25.00$75,000.00  
3/31/2026Sell75,000$26.27$1,970,250.00  
3/27/2026
Ra Capital Management, L.P.
Director
Buy310,700$23.67$7,354,269.00  
3/13/2026Sell14,058$26.26$369,163.08  
3/12/2026Sell6,348$27.37$173,744.76  
3/9/2026Sell2,171$26.84$58,269.64  
2/17/2026Sell417$27.59$11,505.03  
2/13/2026Sell14,055$27.44$385,669.20  
2/12/2026Sell6,349$28.99$184,057.51  
2/9/2026Sell2,171$30.21$65,585.91  
1/20/2026Sell416$32.10$13,353.60  
1/14/2026Sell11,367$32.61$370,677.87  
1/13/2026Sell7,709$32.75$252,469.75  
1/12/2026Sell10,758$32.14$345,762.12  
1/12/2026Sell6,348$32.32$205,167.36  
1/12/2026Sell16,236$32.62$529,618.32  
1/9/2026Sell2,170$33.27$72,195.90  
1/5/2026Sell192,715$35.02$6,748,879.30  
1/2/2026Sell70,037$35.87$2,512,227.19  
11/20/2025Sell1,000,000$43.35$43,350,000.00  
11/13/2025Sell12,742$46.50$592,503.00  
11/13/2025Sell15,000$45.99$689,850.00  
11/12/2025Sell6,933$46.72$323,909.76  
11/11/2025Sell119,524$44.88$5,364,237.12  
11/11/2025Sell15,000$43.98$659,700.00  
11/11/2025Sell200,000$45.44$9,088,000.00  
10/15/2025Sell10,369$43.01$445,970.69  
10/13/2025Sell10,758$42.01$451,943.58  
10/13/2025Sell15,100$42.67$644,317.00  
9/15/2025Sell11,367$36.00$409,212.00  
9/4/2025
Ra Capital Management, L.P.
Director
Buy1,176,470$25.50$29,999,985.00  
9/4/2025Buy588,235$25.50$14,999,992.50  
8/13/2025Sell11,365$12.93$146,949.45  
7/30/2025Sell59,925$14.76$884,493.00  
7/29/2025Sell807$14.00$11,298.00  
7/28/2025Sell12,946$14.04$181,761.84  
7/14/2025Sell11,366$14.59$165,829.94  
7/11/2025Sell10,758$14.45$155,453.10  
7/11/2025Sell15,884$14.51$230,476.84  
5/14/2025Sell11,366$15.29$173,786.14  
(Data available from 1/1/2013 forward)

MLYS Insider Trading Activity - Frequently Asked Questions

The list of insiders at Mineralys Therapeutics includes Adam Scott Levy, Alexander M Gold, Brian Taylor Slingsby, Daphne Karydas, David Malcom Rodman, Jon Congleton, Ra Capital Management, L.P., Samsara Biocapital Gp, Llc, and Srinivas Akkaraju. Learn more on insiders at MLYS.

18.94% of Mineralys Therapeutics stock is owned by insiders. Learn more on MLYS's insider holdings.

The following insiders have purchased MLYS shares in the last 24 months: Ra Capital Management, L.P. ($54,854,250.00), Samsara Biocapital Gp, Llc ($8,100,000.00), and Srinivas Akkaraju ($14,999,992.50).

Insiders have purchased a total of 3,971,701 MLYS shares in the last 24 months for a total of $77,954,242.50 bought.

The following insiders have sold MLYS shares in the last 24 months: Adam Scott Levy ($9,162,672.45), Alexander M Gold ($1,576,112.76), Brian Taylor Slingsby ($50,527,500.00), Daphne Karydas ($764,850.00), David Malcom Rodman ($14,822,315.60), and Jon Congleton ($14,069,307.68).

Insiders have sold a total of 2,911,849 Mineralys Therapeutics shares in the last 24 months for a total of $90,922,758.49 sold.



This page (NASDAQ:MLYS) was last updated on 5/6/2026 by MarketBeat.com Staff.
From Our Partners